Addendum After Press

After preparation of this review the important findings of the ADVANCE study were published (104). In this randomized controlled trial the routine administration of an ACE inhibitor-diuretic combination on serious vascular events in patients with diabetes, was evaluated in 11,140 patients with type 2 diabetes irrespective of initial blood pressure levels or the use of other blood pressure lowering drugs. Compared with patients assigned placebo, those assigned active therapy had a mean reduction in systolic blood pressure of 5.6mmHg and diastolic blood pressure of 2.2 mm Hg. After a mean follow-up period of 4.3 years the relative risk of a major macrovascular or microvascular event was reduced by 9% (861 [15.5%] active versus 938 [16.8%] placebo; hazard ratio 0.91, 95% CI 0.83-1.00, p = 0.04). The relative risk of death from cardiovascular disease was reduced by 18% (211 [3.8%] active versus 257 [4.6%] placebo; 0.82, 0.68-0.98, p = 0.03) and death from any cause was reduced by 14% (408 [7.3%] active versus 471 [8.5%] placebo; 0.86, 0.75-0.98, p = 0.03). The important results of ADVANCE indicate that the routine administration of a fixed combination of perindopril and indapamide to a broad range of patients with diabetes reduces the risks of death and major macrovascular or microvascular complications, irrespective of initial blood pressure level or ancillary treatment with the many other preventive treatments typically provided to diabetic patients today.

Delicious Diabetic Recipes

Delicious Diabetic Recipes

This brilliant guide will teach you how to cook all those delicious recipes for people who have diabetes.

Get My Free Ebook

Post a comment